There are a range of treatments available for prostate cancer depending on the stage of the cancer, the person’s general health, age and more.
Early detection is crucial for positive outcomes from the disease. Together with our Group charity Australian Prostate Cancer, we are funding research focused on the detection, treatment and management of prostate cancer to improve the outlook for the men we love.
Prostate Cancer Support
Current tests for detecting prostate cancer struggle to accurately distinguish between aggressive tumours requiring treatment, versus slow-growing tumours that do not need to be treated at all.
Investigating how different cell types in a prostate tumour interact, to identify the drivers of prostate cancer growth and understand why some treatments fail in some patients.
Progressing pre-clinical studies on a revolutionary formulation of Zytiga that will speed up the drug’s digestion and enhance absorption in the body, to avoid the inconvenience of having to fast before and after taking the drug.
Progressing research into prostate cancer which has become resistant to existing therapies, by focusing on a promising drug Ribociclib and using biomarkers to predict which patients it will work best for.
Producing a “report card” which outlines the outcomes of various prostate cancer treatments to help prostate cancer patients make informed treatment choices when diagnosed with the disease. It will evaluate survival, cancer recurrence, secondary treatment and impacts on urinary, bowel and sexual function for different prostate cancer treatments, based on the experiences of men previously diagnosed with prostate cancer.
Improving early detection of patients whose prostate cancer is more likely to spread to advanced incurable stages, by establishing biomarkers which can distinguish high-risk patients and then develop new treatments to improve the patient’s outcomes and quality of life.
Progressing research on a newly-discovered protein called CDK9 which drives prostate cancer growth, and determine whether CDK9 inhibitors can stop the growth of lethal forms of prostate cancer.
Men with prostate cancer have high levels of unmet need around loss of sexual function following treatment, yet the majority don’t seek help.
Identifying a list of new and existing drugs which show promise in changing an offending hormone receptor in breast cancer from cancer-promoting to cancer-inhibiting, and taking these new drugs to clinical trials.
Contributing to the South Australian Prostate Cancer Clinical Outcomes Collaborative (SA-PCCOC) database which holds data for more than 18,000 men to assist research insights and inform best approaches to care.